## **COVID-19 AND MONKEYPOX UPDATE**

Kirsten Johnson, MPH, CPH, CHES Commissioner of Health

BOARD OF HEALTH

SEPTEMBER 1, 2022



LIVING YOUR BEST LIFE.



## **CURRENT CASE BURDEN**




### **KEY METRICS**

### Key Indicator Statuses Updated on Tuesdays & Thursdays

**Return to Overview** 

#### Rate of COVID-19 cases per 100,000 over 7 days

Total number of new cases in the City of Milwaukee in the last 7 days divided by the City of Milwaukee population and multiplying by 100,000. Population data is based on US Census, 2019.





65.4%

#### City of Milwaukee Adult Vaccination Rate

Total number of adult City of Milwaukee residents who have completed their COVID-19 vaccination series divided by the adult population of the City of Milwaukee. Adult is defined as an individual who is 16 years of age or older. Population data is based on U.S. Census, 2019.

#### CDC Community Levels

The CDC has updated the thresholds and metrics used in assessing a community's COVID-19 levels. The new levels are determined based on new COVID-19 hospital admissions in the past 7 days, percent of staffed inpatients beds occupied by COIVD-19 patients, and total new COVID-19 cases in the past 7 days. The CDC updates these calculations weekly on Thursdays. We will update community level calculations on Fridays.


More information on the measures, thresholds, and individual factors for Milwaukee County can be found at: <u>https://www.cdc.gov/coronavirus/2019-ncov/science/community-levels.html</u>

### MEDIUM COVID-19 COMMUNITY LEVEL

#### You should:


Talk to your healthcare provider about whether you need to wear a mask and take other precautions if you're at high risk for severe illness
Stay up to date with COVID-19 vaccines
Get tested if you have symptoms

### **CURRENT CASE BURDEN**




\*Metric excludes last 4 days to account for delays in reporting and allow trends to stabilize. Data Source: Wisconsin Electronic Disease Surveillance System (WEDSS) via DHS Last Updated: 8/31/2022 10:18:01 AM

### COVID-19 Wastewater Surveillance in Wisconsin



### HOSPITALIZATIONS





## VARIANTS IN WI


### • Omicron is 100% of cases, subvariants of BA.4 and BA.5 are continuing to increase



### Wisconsin SARS-CoV-2 (hCoV-19) Genomic Dashboard

enabled by data from GISAID





Proportion of sequenced strains that are variants of concern (red) and variants being monitored (purple), over time by sample collection date.

Time Period	Variant Label
Weekly -	Pangolin

## VACCINATIONS



## VACCINE UPDATE

- 65.4% of adults (16+) fully vaccinated
- 55.5% of total residents fully vaccinated
- 50.7% of fully vaccinated residents are boosted



LIVING YOUR BEST LIFE.

## **DEMOGRAPHIC TABLE**

#### Vaccinated City of Milwaukee Residents By Race/Ethnicity

Race/Ethnicity	2019 ACS Population Estimate	At Least 1 Dose	Percent Population	Fully Vaccinated	Race/Ethnicity Percent Population Fully Vaxxed	Boosted Individuals	Percent of Fully Vaxxed w Booster
Black or African-American	227,829	108,290	47.5%	97,624	42.8%	43,686	44.7%
Hispanic or Latino	112,817	69,635	61.7%	63,518	56.3%	26,205	41.3%
Other Race	17,258	13,879	80.4%	12,644	73.3%	5,245	41.5%
American Indian or Alaska	2,763	2,178	78.8%	2,022	73.2%	1,006	49.8%
White	208,521	128,175	61.5%	122,282	58.6%	78,260	64.0%
Asian or Pacific Islander	25,360	20,764	81.9%	19,134	75.4%	7,956	41.6%
Unknown		12,672		10,453		3,808	36.4%
Grand Total	594,548	355,593		327,677		166,166	50.7%

#### Vaccinated City of Milwaukee Residents By Age Group

	2019 ACS Population Estimate	At Least 1 Dose	Age Percent of Population with 1 or more doses	Fully Vaccinated	Age Percent of Population fully vaxxed	Boosted Individuals	Percent of Fully Vaxxed w Booster
5 to 11 years	61,519	16,150	26.3%	13,502	21.9%	222	1.6%
12 to 15 years	32,878	17,643	53.7%	15,902	48.4%	4,808	30.2%
16 to 19 years	36,222	18,755	51.8%	16,730	46.2%	5,409	32.3%
20 to 24 years	50,576	30,110	59.5%	26,656	52.7%	9,302	34.9%
25 to 34 years	101,565	64,567	63.6%	58,300	57.4%	24,562	42.1%
35 to 44 years	74,841	53,663	71.7%	49,537	66.2%	23,498	47.4%
45 to 54 years	66,835	48,775	73.0%	45,661	68.3%	24,943	54.6%
55 to 59 years	34,030	25,195	74.0%	23,900	70.2%	14,838	62.1%
60 to 64 years	29,689	24,816	83.6%	23,693	79.8%	16,481	69.6%
65 to 74 years	37,530	36,056	96.1%	34,765	92.6%	27,279	78.5%
75 to 84 years	16,494	14,024	85.0%	13,505	81.9%	10,703	79.3%
85 years and over	8,304	5,797	69.8%	5,497	66.2%	4,119	74.9%
Grand Total	594,548	355,593		327,677		166,166	50.7%



## **CDC UPDATES**

# **CDC UPDATES**

### CHANGE IN GUIDANCE

- Focus on preventing instances of severe COVID-19
- Guidelines are now the same for those who are and are not up to date with vaccination
- No longer recommended:
  - Quarantining if exposed to COVID-19
  - Screening testing of asymptomatic people without known exposures
- Key points:
  - Individuals should know their own risk, using COVID-19 Community Levels to help inform actions
  - Individuals should utilize available prevention and management tools (e.g. vaccination, preexposure prophylaxis, antivirals/medications to treat COVID-19)
  - Those who have COVID should isolate for 5 days and mask for 10 days
  - Those exposed to COVID should mask for 10 days and get tested on day 5



Centers for Disease Control and Prevention. Summary of Guidance for Minimizing the Impact of COVID-19 on Individual persons, Communities, and Health Care Systems – United States, August 2022. Published August 19, 2022. Accessed August 31, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7133e1.htm

### CDC UPDATES VACCINES

FDA NEWS RELEASE

### Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose

The FDA authorized bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months after completing primary or booster vaccination.

The <u>Moderna COVID-19 Vaccine</u>, <u>Bivalent</u> is authorized for use as single booster dose in **individuals 18 years of age and older**.

The <u>Pfizer-BioNTech COVID-19 Vaccine</u>, <u>Bivalent</u> is authorized for use as a single booster dose in **individuals 12 years of age and older**.

ACIP COVID-19 Vaccine Recommendations | CDC

COVID-19 Vaccine Booster Shots | CDC



### CDC UPDATES VACCINES

### **COVID-19 Vaccination Recommendations for Children**

CDC recommends COVID-19 vaccines for everyone ages 6 months and older, and boosters for everyone ages 5 years and older if eligible.

### COVID-19 vaccines available for children include:

#### Pfizer-BioNTech COVID-19 Vaccine

 Children ages 6 months–4 years: Should receive a 3-dose primary series. The first and second doses are separated by 3–8 weeks and the second and third doses are separated by at least 8 weeks. Currently, a booster dose is not authorized for this age group.

#### Moderna COVID-19 Vaccine

Children ages 6 months–5 years: Should receive a 2-dose primary series separated by 4–8 weeks. Currently, a booster
dose is not authorized for children in this age group who receive a Moderna primary series.

### COVID-19 Vaccination for Children | CDC

## MASK GUIDANCE



# **CURRENT CDC GUIDANCE**

- In general, people do not need to wear masks when outdoors. Wear a mask if you are sick and need to be around others or are <u>caring for someone who has COVID-19.</u>
- If the <u>COVID-19 Community Level</u> where you live is
  - Low
    - Wear a mask based on your personal preference, informed by your personal level of risk.
  - Medium
    - If you are at risk for <u>severe illness</u>, talk to your healthcare provider about wearing masks indoors in public.
    - If you live with or will gather with someone at risk for severe illness, wear a mask when indoors with them.
  - High
    - If you are 2 or older, wear a well-fitting mask indoors in public, regardless of vaccination status or individual risk (including in K-12 schools and other community settings).




Centers for Disease Control and Prevention. Omicron Variant: What You Need to Know. Published January 21, 2022. Accessed June 8, 2022. https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html

# MONKEYPOX



# CITY OF MILWAUKEE CASES

- First case identified July 8<sup>th</sup>, 2022
- 3 cases in July
- 22 cases in August
- 56 total cases in Wisconsin
- Nationally cases are plateauing



Cases Reported in 2022



1. U.S. Monkeypox Case Trends Reported to CDC | Monkeypox | Poxvirus | CDC

Monkeypox Case Trends Reported to CDC

## SYMPTOMS

- People with monkeypox get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or anus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth.
- The rash will go through several stages, including scabs, before healing.
- The rash can initially look like pimples or blisters and may be painful or itchy.



Signs and Symptoms | Monkeypox | Poxvirus | CDC

# HOW IT SPREADS

- Monkeypox can spread to anyone through close, personal, often skin-to-skin contact, including:
- Direct contact with monkeypox rash, scabs, or body fluids from a person with monkeypox.
- Touching objects, fabrics (clothing, bedding, or towels), and surfaces that have been used by someone with monkeypox.
- Contact with respiratory secretions.



How It Spreads | Monkeypox | Poxvirus | CDC

# TREATMENT

ANTIVIRAL

- Monkeypox and smallpox viruses are genetically similar, which means that antiviral drugs and vaccines developed to protect against smallpox may be used to prevent and treat monkeypox virus infections.
- Antivirals, such as tecovirimat (TPOXX), may be recommended for people who are more likely to get severely ill, like patients with weakened immune systems.
- Most people with monkeypox recover fully within 2 to 4 weeks without the need for medical treatment.



Treatment | Monkeypox | Poxvirus | CDC

### **TREATMENT** VACCINE

- Two vaccines may be used for the prevention of monkeypox disease:
  - JYNNEOS vaccine is approved for the prevention of monkeypox and smallpox disease.
  - ACAM2000 vaccine is approved for immunization against smallpox disease and made available for use against monkeypox under an Expanded Access Investigational New Drug (EA-IND) protocol.
- People can be vaccinated after exposure to monkeypox virus to help prevent monkeypox disease (i.e., post-exposure prophylaxis).



Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak | Monkeypox | Poxvirus | CDC

## **QUESTIONS?**

